Does dabigatran etexilate have predictable pharmacokinetics, pharmacodynamics, and tolerability in healthy male subjects?
Dabigatran etexilate demonstrates predictable pharmacokinetics and pharmacodynamics with good tolerability in healthy males, supporting further clinical investigation for thromboembolic disorders.
These data suggest that dabigatran etexilate is a promising novel oral DTI with predictable PK and PD characteristics and good tolerability. Further investigation of dabigatran etexilate for the treatment and prophylaxis of patients with arterial and venous thromboembolic disorders, acute coronary syndromes and other medical conditions is warranted.
Stangier et al. (Tue,) studied this question.